Travere Therapeutics, Inc. Common Stock (TVTX) Stock
NASDAQ · TVTX
60.34
Fundamentals
Market cap
$5.60B
Price / Earnings ratio
-131.5x
Price / Sales ratio
9.7x
Price / Book ratio
233.0x
Return on assets
-4.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
NeutralTVTXSeptember 23, 2026
Business WireNeutral
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
TVTX

Business Wire
Travere Therapeutics Announces Planned Chief Executive Officer Transition
NeutralTVTXSeptember 21, 2026
Business WireNeutral
Travere Therapeutics Announces Planned Chief Executive Officer Transition
TVTX

Business Wire
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
NeutralTVTXSeptember 17, 2026
Business WireNeutral
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
TVTX

Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NeutralTVTXSeptember 11, 2026
Business WireNeutral
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TVTX
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy7
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
589M389M194M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
726M479M240M0
Revenue to Profit
2025$490.7M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-25.5M
Net incomeEarnings
EPS forecast
Actual EPS
$0.07
Q2FY26
The market is expecting earnings per share of $0.07 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
NeutralTVTXSeptember 23, 2026
Business WireNeutral
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
TVTX

Business Wire
Travere Therapeutics Announces Planned Chief Executive Officer Transition
NeutralTVTXSeptember 21, 2026
Business WireNeutral
Travere Therapeutics Announces Planned Chief Executive Officer Transition
TVTX

Business Wire
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
NeutralTVTXSeptember 17, 2026
Business WireNeutral
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
TVTX

Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NeutralTVTXSeptember 11, 2026
Business WireNeutral
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TVTX

MarketBeat
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
NeutralTVTXAugust 18, 2026
MarketBeatNeutral
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
TVTX

Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NeutralTVTXAugust 12, 2026
Business WireNeutral
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TVTX

Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
NeutralTVTXAugust 5, 2026
Business WireNeutral
Travere Therapeutics to Participate at Upcoming Investor Conferences
TVTX

MarketBeat
Travere Therapeutics Q2 Earnings Call Highlights
NeutralTVTXAugust 5, 2026
MarketBeatNeutral
Travere Therapeutics Q2 Earnings Call Highlights
TVTX

Zacks Investment Research
Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say
NeutralTVTXAugust 4, 2026
Zacks Investment ResearchNeutral
Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say
TVTX

Zacks Investment Research
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
NeutralTVTXAugust 4, 2026
Zacks Investment ResearchNeutral
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
TVTX
About Travere Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees497
CEODr. Eric M. Dube Ph.D.
IPO DateNov 8, 2012
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Eric M. Dube Ph.D. | President, CEO & Director | 1973 |
| Mr. Christopher Cline C.F.A. | Chief Financial Officer | 1985 |
| Dr. William E. Rote Ph.D. | Chief Research Officer | 1963 |
| Mr. Peter Heerma | Chief Commercial Officer | 1971 |
| Dr. Jula Inrig M.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 1975 |
| Ms. Sandra Calvin | SVP & Chief Accounting Officer | 1966 |
| Ms. Nivi Nehra | Vice President of Corporate Communications & Investor Relations | — |
| Ms. Elizabeth E. Reed J.D. | Chief Legal Officer, General Counsel & Secretary | 1971 |
| Ms. Angela Giannantonio | Chief People Officer | — |
| Mr. Casey Logan | Chief Business Officer | — |
Fundamentals
Valuation
Market cap$5.60B
Price-to-sales ratio9.66
Price-to-book value233.02
Price-earnings ratio-131.50
Return on Equity-27.00%
Return on Sales-2.00%
Return on Assets-4.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.45
Income Statement
Average volume1,500,192
EBITDA$62.75M
1 year high (52w)$68.73
1 year low (52w)$22.06
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
7 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$77.14
Est return
29.78%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.1 | +15.1 | -3.5 | +10.9 | ||||||||
| 2022 | -10.1 | +2.8 | -3.2 | -9.7 | -9.4 | +7.2 | -6.2 | +16.8 | -12.2 | -14.7 | -9.9 | +7.6 |
| 2023 | +8.4 | +0.3 | +3.4 | -4.2 | -20.9 | -15.6 | +10.5 | -14.6 | -39.9 | -23.0 | -6.5 | +40.0 |
| 2024 | -6.6 | -12.1 | -2.0 | -24.4 | +23.7 | +6.5 | +15.2 | +2.5 | +45.7 | +25.1 | +7.1 | -11.0 |
| 2025 | +7.9 | +5.8 | -9.5 | +19.3 | -27.6 | -4.6 | +5.0 | +12.0 | +31.7 | +41.8 | +2.5 | +8.6 |
| 2026 | -21.3 | -10.0 | +0.6 | +34.1 | +6.9 | +26.1 | -0.8 | +20.6 | -9.5 |



